SCHEMBL9976757

SCHEMBL9976757

c1ccc(-c2cc3c(cc(-c4ccccc4)c4ccc(-c5ccc6ccccc6c5)nc43)c3nc(-c4ccc5ccccc5c4)ccc23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.47
CYP1B1 Q16678 1/20 0.47
CYP1A2 P05177 4/20 0.44
ALDH1A1 P00352 3/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CYP17A1 P05093 1/20 0.42
CYP19A1 P11511 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 1/20 0.41
AR P10275 1/20 0.41
MAPT P10636 1/20 0.41
NFKB1 P19838 1/20 0.41
RAB9A P51151 1/20 0.41
GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9976734 0.94 CYP1A1 (0.47) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL9976756 0.94 CYP1A2 (0.46) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL184973 0.89 CYP1A1 (0.56) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL29358046 0.89 CYP1A1 (0.56) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL29373621 0.89 CYP1A1 (0.56) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL439445 0.87 CYP1A1 (0.58) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL13458815 0.87 CYP1A1 (0.54) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL9976753 0.85 CYP1A2 (0.40) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL23433534 0.83 CYP1A1 (0.48) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9
SCHEMBL440520 0.83 CYP1A1 (0.53) CYP1A1CYP1B1CYP1A2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877354-B2 Heterocyclic compound and organic light-emitting device using the same CANON KABUSHIKI KAISHA (JP) 2014-11-04 US disclosed
US-8877354-B2 Heterocyclic compound and organic light-emitting device using the same CANON KABUSHIKI KAISHA (JP) 2014-11-04 US disclosed
US-20120153270-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2012-06-21 US disclosed
US-20120153270-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120153270-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME ORC3, CYP1A1, CRY1 CYP1A1 2/4885CYP1B1 17/4885CYP1A2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.